Monocyte chemotactic protein-1 expression as a prognosic biomarker in patients with solid tumor: A meta analysis

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 7, 2014, Pages 3876-3886

  Wang, Hong ^a   Zhang, Qiongwen ^a   Kong, Hongyu ^a   Zeng, Yunhui ^a   Hao, Meiqin ^a   Yu, Ting ^a   Peng, Jing ^a   Xu, Zhao ^a   Chen, Jingquan ^a   Shi, Huashan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Cancer; Meta analysis; Monocyte chemotactic protein 1; Overall survival; Prognosis

Indexed keywords

CCL2 PROTEIN, HUMAN; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR MARKER;

BIOSYNTHESIS; DISEASE FREE SURVIVAL; HUMAN; META ANALYSIS; METABOLISM; MORTALITY; NEOPLASM; PATHOLOGY; PROGNOSIS;

CHEMOKINE CCL2; DISEASE-FREE SURVIVAL; HUMANS; NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84906273295     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Frade J, Mellado M, del Real G, Gutierrez-Ramos J, Lind P and Martinez-A C. Characterization of the CCR2 chemokine receptor: functional CCR2 receptor expression in B cells. J Immunol 159: 5576-5584.
2. Matsushima K, Larsen CG, DuBois GC and Oppenheim JJ. Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med 169: 1485-1490.
3. Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ and Fogelman AM. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A 87: 5134-5138.
4. Lu Y, Cai Z, Xiao G, Liu Y, Keller ET, Yao Z and Zhang J. CCR2 expression correlates with prostate cancer progression. J Cell Biochem 2007; 101: 676-685.
5. Loberg RD, Ying C, Craig M, Yan L, Snyder LA and Pienta KJ. CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia 2007; 9: 556-62.
6. Allavena P, Bianchi G, Zhou D, Van Damme J, Jílek P, Sozzani S and Mantovani A. Induction of natural killer cell migration by monocyte chemotactic protein-1, -2 and -3. Eur J Immunol 1994; 24: 3233-3236.
7. Proost P, Wuyts A and Van Damme J. Human monocyte chemotactic proteins-2 and -3: structural and functional comparison with MCP-1. J Leukoc Biol 1996; 59: 67-74.
8. Dwyer R, Potter-Beirne S, Harrington K, Lowery A, Hennessy E, Murphy J, Barry F, O'Brien T and Kerin M. Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res 2007; 13: 5020-5027.
9. Balkwill FR. The chemokine system and cancer. J Pathol 2012; 226: 148-157.
10. Negus R, Stamp G, Relf M, Burke F, Malik S, Bernasconi S, Allavena P, Sozzani S, Mantovani A and Balkwill FR. The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J Clin Invest 1995; 95: 2391.
11. Lu Y, Cai Z, Galson DL, Xiao G, Liu Y, George DE, Melhem MF, Yao Z and Zhang J. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate 2006; 66: 1311-1318.
12. Saji H, Koike M, Yamori T, Saji S, Seiki M, Matsushima K and Toi M. Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer 2001; 92: 1085-1091.
13. Huang S, Singh RK, Xie K, Gutman M, Berry KK, Bucana CD, Fidler IJ and Bar-Eli M. Expression of the JE/MCP-1 gene suppresses metastatic potential in murine colon carcinoma cells. Cancer Immunol Immunother 1994; 39: 231-238.
14. Dehqanzada ZA, Storrer CE, Hueman MT, Foley RJ, Harris KA, Jama YH, Kao TC, Shriver CD, Ponniah S and Peoples GE. Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients. Clin Cancer Res 2006; 12: 478-486.
15. Mestdagt M, Polette M, Buttice G, Noël A, Ueda A, Foidart JM and Gilles C. Transactivation of MCP-1/CCL2 by β-catenin/TCF-4 in human breast cancer cells. Int J Cancer 2006; 118: 35-42.
16. Fujimoto H, Sangai T, Ishii G, Ikehara A, Nagashima T, Miyazaki M and Ochiai A. Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression. Int J Cancer 2009; 125: 1276-1284.
17. Zhang L, Khayat A, Cheng H and Graves DT. The pattern of monocyte recruitment in tumors is modulated by MCP-1 expression and influences the rate of tumor growth. Lab Invest 1997; 76: 579-590.
18. Fang WB, Jokar I, Zou A, Lambert D, Dendukuri P and Cheng N. CCL2/CCR2 chemokine signaling coordinates survival and motility of breast cancer cells through Smad3 protein-and p42/44 mitogen-activated protein kinase (MAPK)-dependent mechanisms. J Biol Chem 2012; 287: 36593-36608.
19. Hefler L, Tempfer C, Heinze G, Mayerhofer K, Breitenecker G, Leodolter S, Reinthaller A and Kainz C. Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients. Br J Cancer 1999; 81: 855.
20. Freels S. Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints. Stat Med 2004; 23: 1817.
21. Mantel N and Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. The Challenge of Epidemiology: Issues and Selected Readings 2004; 1: 533-553.
22. Qian Q, Sun WK, Zhan P, Zhang Y, Song Y and Yu LK. Role of monocyte chemoattractant protein-1, tumor necrosis factor-alpha and interleukin-6 in the control of malignant pleural effusion and survival in patients with primary lung adenocarcinoma. Int J Biol Markers 20121; 27: e118-124.
23. Zhang XW, Qin X, Qin CY, Yin YL, Chen Y and Zhu HL. Expression of monocyte chemoattractant protein-1 and CC chemokine receptor 2 in non-small cell lung cancer and its significance. Cancer Immunol Immunother 2013; 62: 563-570.
24. Shirotake S, Miyajima A, Kosaka T, Tanaka N, Kikuchi E, Mikami S, Okada Y and Oya M. Regulation of monocyte chemoattractant protein-1 through angiotensin II type 1 receptor in prostate cancer. Am J Pathol 2012; 180: 1008-1016.
25. Lu X, Qian CN, Mu YG, Li NW, Li S, Zhang HB, Li SW, Wang FL, Guo X and Xiang YQ. Serum CCL2 and serum TNF-α-Two new biomarkers predict bone invasion, post-treatment distant metastasis and poor overall survival in nasopharyngeal carcinoma. Eur J Cancer 2011; 47: 339-346.
26. Yoshidome H, Kohno H, Shida T, Kimura F, Shimizu H, Ohtsuka M, Nakatani Y and Miyazaki M. Significance of monocyte chemoattractant protein-1 in angiogenesis and survival in colorectal liver metastases. Int J Oncol 2009; 34: 923-930.
27. Heimdal JH, Kross K, Klementsen B, Olofsson J and Aarstad HJ. Stimulated monocyte IL-6 secretion predicts survival of patients with head and neck squamous cell carcinoma. BMC Cancer 2008; 8: 34.
28. Watanabe H, Miki C, Okugawa Y, Toiyama Y, Inoue Y and Kusunoki M. Decreased expression of monocyte chemoattractant protein-1 predicts poor prognosis following curative resection of colorectal cancer. Dis Colon Rectum 2008; 51: 1800-1805.
29. Lambeck AJ, Crijns AP, Leffers N, Sluiter WJ, Klaske A, Braid M, van der Zee AG, Daemen T, Nijman HW and Kast WM. Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7. Clin Cancer Res 2007; 13: 2385-2391.
30. Koide N, Nishio A, Sato T, Sugiyama A and Miyagawa S. Significance of macrophage chemoattractant protein-1 expression and macrophage infiltration in squamous cell carcinoma of the esophagusa. Am J Gastroenterol 2004; 99: 1667-1674.
31. Monti P, Leone BE, Marchesi F, Balzano G, Zerbi A, Scaltrini F, Pasquali C, Calori G, Pessi F, Sperti C, Di Carlo V, Allavena P, Piemonti L. The CC chemokine MCP-1/CCL2 in pancreatic cancer progression regulation of expression and potential mechanisms of antimalignant activity. Cancer Res 2003; 63: 7451-7461.
32. Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, Koike M, Inadera H and Matsushima K. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 2000; 6: 3282-3289.
33. Tsui KH, Shvarts O, Smith RB, Figlin RA, deKernion JB, Belldegrun A. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000; 163: 1090-1095.
34. Javidan J, Stricker HJ, Tamboli P, Amin MB, Peabody JO, Deshpande A, Menon M, Amin MB. Prognostic significance of the 1997 TNM classification of renal cell carcinoma. J Urol 1999; 162: 1277-1281.
35. Valković T, Lučin K, Krstulja M, Dobi-Babić R and Jonjić N. Expression of monocyte chemotactic protein-1 in human invasive ductal breast cancer. Pathol Res Pract 1998; 194: 335-340.
36. Mantovani A, Schioppa T, Porta C, Allavena P and Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 2006; 25: 315-322.
37. Arenberg DA, Keane MP, DiGiovine B, Kunkel SL, Strom SR, Burdick MD, Iannettoni MD and Strieter RM. Macrophage infiltration in human non-small-cell lung cancer: the role of CC chemokines. Cancer Immunol Immunothe 2000; 49: 63-70.
38. Deshmane SL, Kremlev S, Amini S and Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 2009; 29: 313-326.
39. Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, Kleinman HK, Oppenheim JJ and Murphy WJ. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000; 96: 34-40.
40. Gazzaniga S, Bravo AI, Guglielmotti A, van Rooijen N, Maschi F, Vecchi A, Mantovani A, Mordoh J and Wainstok R. Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J Invest Dermatol 2007; 127: 2031-2041.
41. Hong KH, Ryu J and Han KH. Monocyte chemoattractant protein-1-induced angiogenesis is mediated by vascular endothelial growth factor-A. Blood 2005; 105: 1405-1407.
42. Goede V, Brogelli L, Ziche M and Augustin HG. Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1. Int J Cancer 1999; 82: 765-770.
43. Ohta M, Kitadai Y, Tanaka S, Yoshihara M, Yasui W, Mukaida N, Haruma K and Chayama K. Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas. Int J Cancer 2002; 102: 220-224.
44. Qian BZ and Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141: 39-51.
45. Condeelis J and Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006; 124: 263-266.
46. Ma J, Wang Q, Fei T, Han JD, Chen YG. MCP-1 mediates TGF-β-induced angiogenesis by stimulating vascular smooth muscle cell migration. Blood 2007; 109: 987-994.
47. Vitiello PF, Shainheit MG, Allison EM, Adler EP and Kurt RA. Impact of tumor-derived CCL2 on T cell effector function. Immunol Lett 2004; 91: 239-245.
48. Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K and Stanners CP. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 1989; 57: 327-334.
49. Abelev G. Alpha-fetoprotein in ontogenesis and its association with malignant tumors. Adv Cancer Res 1971; 14: 278.
50. Ferlay J, Parkin D and Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-781.
51. Stewart LA and Parmar MK. Meta-analysis of the literature or of individual patient data: is there a difference? Lancet 1993; 341: 418-422.
52. Hayes DF, Isaacs C and Stearns V. Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia 2001; 6: 375-392.
53. Tong J, Sun X, Cheng H, Zhao D, Ma J, Zhen Q, Cao Y, Zhu H and Bai J. Expression of p16 in non-small cell lung cancer and its prognostic significance: a meta-analysis of published literatures. Lung Cancer 2011; 74: 155-163.
54. Rosenthal R. The file drawer problem and tolerance for null results. Psychological bulletin 1979; 86: 638.
55. Egger M, Zellweger-Zähner T, Schneider M, Junker C, Lengeler C and Antes G. Language bias in randomised controlled trials published in English and German. Lancet 1997; 350: 326-329.
56. Raman D, Baugher PJ, Thu YM and Richmond A. Role of chemokines in tumor growth. Cancer Lett 2007; 256: 137-165.
57. Scargle JD. Publication bias: the "file-drawer" problem in scientific inference. Journal of Scientific Exploration 2000; 14: 91-106.